Related Experiment Video
Updated: Jul 4, 2025
05:34
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
583
Updates on New Therapies for Patients with CKD.
Tushar Tarun1, Sai Nikhila Ghanta1, Vincz Ong1
1Division of Cardiology, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Kidney International Reports
|February 5, 2024
Summary
New drugs offer hope for chronic kidney disease (CKD) patients facing high cardiovascular risk. This review details benefits and challenges of newer CKD treatments, providing guidance for optimal patient selection.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Global increase in chronic kidney disease (CKD) patients.
- CKD patients face disproportionately higher cardiovascular (CV) event risk.
- Residual cardiorenal risk persists despite guideline-based management.
Purpose of the Study:
- Discuss CKD pathophysiology based on recent studies.
- Explore benefits and limitations of novel CKD pharmacotherapies.
- Provide an evidence-based algorithm for selecting patients for newer drug therapies.
Main Methods:
- Literature review focusing on recent publications.
- Analysis of landmark trial data for drug selection criteria.
- Synthesis of information on CKD pathophysiology and emerging treatments.
Main Results:
- New drugs like ARNI, SGLT2i, GLP-1 agonists, and finerenone show efficacy in CKD.
- Underrecognized benefits and challenges associated with these novel agents.
- Identification of patient subgroups who may benefit most from specific therapies.
Conclusions:
- Novel pharmacotherapies hold potential to transform CKD care.
- Careful consideration of benefits and challenges is crucial for effective prescribing.
- Further research is needed for CKD patients with nephrotic range proteinuria or uncontrolled hypertension.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
01:22Heart Failure Drugs: Diuretics
381
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
381
01:11Renal Failure: Dose Adjustments
89
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
89
01:27Dialysis
314
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
314
01:17Factors Affecting Renal Clearance: Renal Impairment
95
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
95
01:28Drug Therapy
44
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
44